Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda
NCT ID: NCT01578447
Last Updated: 2014-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
356 participants
INTERVENTIONAL
2012-04-30
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acceptability of Depo-subQ in Uniject
NCT01667276
Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate
NCT00770887
Modifiers of Tenofovir in the Female Genital Tract
NCT03377608
Lower Dose Depo Provera® Contraceptive Injection
NCT02732418
Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood
NCT02509767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depo-SubQ Provera 104 in Uniject
DepoSubQ Provera 104 in Uniject
DepoSubQ Provera 104 in Uniject
Intramuscular DMPA
Intramuscular DMPA
Intramuscular DMPA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DepoSubQ Provera 104 in Uniject
DepoSubQ Provera 104 in Uniject
Intramuscular DMPA
Intramuscular DMPA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Woman aged 18-45
* Wishes to prevent pregnancy by use of injectable contraception and intends to continue using injectable contraception for next nine months
* Medically eligible for injectable contraception
* Capable of providing informed consent
* Willing to provide contact information
* Agrees to trial participation
* Intends to live in the area for the next nine months
* May or may not be currently using a first-line antiretroviral therapy regimen (includes: AZT/3TC/EFV; AZT/3TC/NVP; CBV/EFV; D4T/3TC/EFV; D4T/3TC/NVP; TDF/3TC/EFV; TDF/3TC/NVP)
Exclusion Criteria
* Desires pregnancy within next nine months
* Contraindications to using injectable contraception
* On second-line antiretroviral therapy regimen
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Society of Family Planning
OTHER
Bill and Melinda Gates Foundation
OTHER
Rakai Health Sciences Program
OTHER
Johns Hopkins Bloomberg School of Public Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ronald Gray
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ron H Gray, MD, MSC
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins Bloomberg School of Public Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rakai Health Sciences Program
Kalisizo, , Uganda
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Polis CB, Nakigozi GF, Nakawooya H, Mondo G, Makumbi F, Gray RH; Members of the Rakai Health Sciences Program Sayana Press study team. Preference for Sayana(R) Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial. Contraception. 2014 May;89(5):385-95. doi: 10.1016/j.contraception.2013.11.008. Epub 2013 Nov 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00003213
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.